Type 2 & other diabetes

Efficacy and safety of switching to iGlarLixi from premixed insulin therapy in patients with type 2 diabetes: A real‐world experience

Diabet MedPublished Retrospective cohort study

Authors' conclusion

Switching from premixed insulin to iGlarLixi is a safe and effective strategy to simplify therapy and improve glycaemic management. Insulin resistance may influence response.

Study context

Population
Adults with T2D who transitioned from premixed insulin to iGlarLixi, July 2020–July 2023, Taipei Veterans General Hospital; mean age 67.6 ± 10.5 years
Participants
40 adults
Exposure
Switch from premixed insulin to iGlarLixi
  • iGlarLixin = 40
Outcome
HbA1c change in patients with baseline HbA1c >58 mmol/mol (7.5%)
Follow-up
6 months
Methodological detailssingle-centre, real-world
  • Single-centre
  • Real-world

Main finding

As reported in the abstract

HbA1c, patients with baseline HbA1c >58 mmol/mol (7.5%, n = 28)

HbA1c decreased from baseline to 6 months

from 79 ± 18 (9.4% ± 1.7%) to 67 ± 18 mmol/mol (8.2% ± 1.6%)

p = 0.01

Achieved HbA1c ≤53 mmol/mol (7.0%)

23.1%

Observational data: associations, not effects.

Further findings

HbA1c, patients previously on 40-50 units/day of premix insulin (largest reduction)

HbA1c decreased
from 83 ± 21 [9.8% ± 1.9%] to 65 ± 15 mmol/mol [8.1% ± 1.4%], p = 0.037

Total insulin dose and injection frequency

Total insulin dose and injection frequency significantly decreased
P < 0.001

Patients with pre-existing hypoglycaemia

Glycaemic control remained stable despite reductions in insulin dose and injection frequency
P = 0.001, p = 0.032, respectively

Predictors of suboptimal glycaemic response

Higher HOMA-IR significantly associated with suboptimal glycaemic response in multivariate model
P = 0.037

Safety

Hypoglycaemia incidence dropped
from 60.0% to 12.5% (p < 0.001)

Original publication

Efficacy and safety of switching to iGlarLixi from premixed insulin therapy in patients with type 2 diabetes: A real‐world experience. Diabet Med. Published 1 April 2026. doi:10.1111/dme.70275

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.